Deep learning-based classifier for carcinoma of unknown primary using methylation quantitative trait loci.

Journal: Journal of neuropathology and experimental neurology
PMID:

Abstract

Cancer of unknown primary (CUP) constitutes between 2% and 5% of human malignancies and is among the most common causes of cancer death in the United States. Brain metastases are often the first clinical presentation of CUP; despite extensive pathological and imaging studies, 20%-45% of CUP are never assigned a primary site. DNA methylation array profiling is a reliable method for tumor classification but tumor-type-specific classifier development requires many reference samples. This is difficult to accomplish for CUP as many cases are never assigned a specific diagnosis. Recent studies identified subsets of methylation quantitative trait loci (mQTLs) unique to specific organs, which could help increase classifier accuracy while requiring fewer samples. We performed a retrospective genome-wide methylation analysis of 759 carcinoma samples from formalin-fixed paraffin-embedded tissue samples using Illumina EPIC array. Utilizing mQTL specific for breast, lung, ovarian/gynecologic, colon, kidney, or testis (BLOCKT) (185k total probes), we developed a deep learning-based methylation classifier that achieved 93.12% average accuracy and 93.04% average F1-score across a 10-fold validation for BLOCKT organs. Our findings indicate that our organ-based DNA methylation classifier can assist pathologists in identifying the site of origin, providing oncologists insight on a diagnosis to administer appropriate therapy, improving patient outcomes.

Authors

  • Adam Walker
    Department of Pathology, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, United States.
  • Camila S Fang
    Department of Pathology, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, United States.
  • Chanel Schroff
    Department of Pathology, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, United States.
  • Jonathan Serrano
    Department of Pathology, New York University School of Medicine, New York, NY, USA.
  • Varshini Vasudevaraja
    Department of Pathology, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, United States.
  • Yiying Yang
    Eight-year Program of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Sarra Belakhoua
    Department of Pathology, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, United States.
  • Arline Faustin
    Department of Pathology, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, United States.
  • Christopher M William
    Department of Pathology, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, United States.
  • David Zagzag
    Department of Pathology, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, United States.
  • Sarah Chiang
    Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Andres Martin Acosta
    Department of Pathology, Indiana University, Indianapolis, IN, United States.
  • Misha Movahed-Ezazi
    Department of Pathology, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, United States.
  • Kyung Park
    Department of Pathology, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, United States.
  • Andre L Moreira
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Farbod Darvishian
    Department of Pathology, NYU Grossman School of Medicine, New York, NY, USA.
  • Kristyn Galbraith
    Department of Pathology, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, United States.
  • Matija Snuderl
    Department of Pathology, New York University, New York, NY, USA.